Nonetheless, loss of MSH2 was significantly associated with poor tumor differentiation (p = 0.01), and loss of MSH6 expression was more frequently observed in patients with signet-ring cell adenocarcinomas and mucinous adenocarcinomas, compared to those with NOS adenocarcinomas (p = 0.001). This evidence concerns the gene MSH2 and adenocarcinoma.